Searchable abstracts of presentations at key conferences in endocrinology

ea0020htc3 | Hot topics: Clinical | ECE2009

ESE Young Investigator Award

Assie Guillaume , de Reynies Aurelien , Rickman David , Tissier Frederique , Groussin Lionel , Rene-Corail Fernande , Dousset Bertrand , Bertagna Xavier , Clauser Eric , Bertherat Jerome

Diagnosing malignancy and assessing the prognosis of adrenocortical tumors is challenging. The aim is to identify molecular predictors of malignancy and of survival.Patients and methods: Of 153 unilateral adrenocortical tumors were studied by microarray (n=92) or RT-qPCR (n=148). A 2-gene predictor of malignancy was built using the disease-free survival as the end-point in a training cohort (n=47), then validated in an independent va...

ea0016p311 | Endocrine tumours | ECE2008

Parathyroid-hormone related- Peptide and PTHrP receptor type 1 are expressed in human adrenocortical carcinoma and regulate cell proliferation and apoptosis in H295R an adrenocortical-derived cell line

Rizk-Rabin Marthe , Assie Guillaume , Fernande Fernande , Perlemoine Karine , Hamzaoui Hinda , Tissier Frederique , Lieberherr Michele , Bertagna Xavier , Bertherat Jeroome , Bouizar Zhor

Adrenocortical tumor (ACT) is a rare, heterogeneous malignancy whose pathogenesis is unclear. The oncoprotein PTHrP, found in many common tumors, can regulate their growth in an autocrine/paracrine fashion through the receptor PTH-R1. Little is known about the role of PTHrP in ACT. We monitored the synthesis of PTHrP and PTH-R1 in a series of 25 ACT: 12 adrenocortical carcinoma (ACC), 13 adrenocortical adenoma (ACA), and investigated the effects of PTHrP (1–34) on H295R c...

ea0056oc7.1 | Genomic and clinical aspects of endocrine tumours | ECE2018

Molecular classification of benign adrenocortical tumors: an integrated genomic study

Faillot Simon , Neou Mario , Espiard Stephanie , Vaczlavik Anna , Garinet Simon , Luscap-Rondof Windy , Jouinot Anne , Drougat Ludivine , Groussin Lionel , Perlemoine Karine , Rene-Corail Fernande , Ragazzon Bruno , Rizk-Rabin Marthe , Libe Rossella , Tissier Frederique , De Reynies Aurelien , Bertherat Jerome , Assie Guillaume

Benign adrenal tumors correspond to a spectrum of distinct tumors, including uni- and bilateral diseases with distinct morphological features, and various steroid hormone secretion types and levels. The aim is to study this variability at the molecular level using pan-genomic approaches.Methods: One hundred and forty six benign adrenal tumors, including adrenocortical adenomas (ACA, N=), primary macronodular adrenal hyperplasia (PMAH, N=), and primary pi...

ea0056oc11.2 | Clinical practice in endocrine tumours: combining conventional and molecular features | ECE2018

Molecular classifiers refine the prognostic stratification of adrenocortical carcinoma

Jouinot Anne , Assie Guillaume , Fassnacht Martin , Libe Rossella , Garinet Simon , Jacob Louis , Faillot Simon , Hamzaoui Nadim , Neou Mario , Sakat Julien , Perlemoine Karine , Sibony Mathilde , Tissier Frederique , Dousset Bertrand , Sbiera Silviu , Ronchi Cristina , Kroiss Matthias , Korpershoek Esther , De Krijger Ronald , Waldmann Jens , Quinkler Marcus , Tabarin Antoine , Chabre Olivier , Coste Joel , Luconi Michaela , Mannelli Massimo , Groussin Lionel , Bertagna Xavier , Baudin Eric , Amar Laurence , Beuschlein Felix , Bertherat Jerome

Background: Adrenocortical cancer (ACC) is an aggressive tumour with heterogeneous prognosis. Pan-genomic studies identified molecular subgroups of ACC, remarkably associated with outcome. For routine prospective use, targeted molecular measures are needed, combined into reasonably easy and cheap techniques. The aim was to develop and validate different combinations of targeted molecular markers reflecting the molecular subgroup, and compare their prognostic value to standard ...